Luizon, Marcelo R. [UNESP]Caldeira-Dias, Mayara [UNESP]Deffune, Elenice [UNESP]Fernandes, Karla S.Cavalli, Ricardo C.Tanus-Santos, José E.Sandrim, Valéria C. [UNESP]2018-12-112018-12-112016-07-01Pharmacogenomics, v. 17, n. 10, p. 1121-1127, 2016.1744-80421462-2416http://hdl.handle.net/11449/173300Aim: Over 40% of patients with pre-eclampsia are nonresponsive to antihypertensive therapy, but the underlying mechanisms are unknown. We examined the effects of plasma from nonresponsive and responsive patients on endothelial gene expression. Patients & methods: PCR array was performed in human umbilical vein endothelial cells (HUVEC) incubated with plasma from nonresponsive (n = 4) and responsive (n = 4) patients. Gene networks and interactions with antihypertensive drugs used in pre-eclampsia were identified by Ingenuity Pathway Analysis. Results: Nifedipine and hydralazine act by upregulate or downregulate genes found to be downregulated or upregulated in HUVEC incubated with plasma from nonresponsive patients. Conclusion: Our novel findings suggest that plasma from nonresponsive and responsive patients evoke different responses in HUVEC, and might advance the pharmacogenomics research in pre-eclampsia.1121-1127engantihypertensive drugsgene expressionhuman umbilical vein endothelial cellshydralazinenifedipinepathway analysisPCR arraypharmacogenomicspre-eclampsiaArtigo10.2217/pgs-2016-0033Acesso restrito2-s2.0-84979574365